Allogeneic hematopoietic cell transplantation (HCT) is increasingly offered to older adults
with hematologic malignancies, even though nonrelapse mortality remains a major concern …

Poor long-term outcomes for many hematologic conditions that are standard indications in
younger adults have naturally pushed the potentially curative, albeit toxic, procedure of …

Historically, the high toxicities of allogeneic hematopoietic cell transplantation (HCT)
precluded this therapy in older adults. However, with more tolerable regimens, better donor …

Demographic trends establish that older adults are the fastest growing segment of
population, with over 19% of the population expected to be aged> 65 years by 2030. As the …

Allogeneic hematopoietic cell transplantation (HCT) is no longer exclusively for the young.
With an aging population, development of non‐intensive remission‐inducing strategies for …

Cure of malignant and non-malignant hematological diseases is potentially possible after
allogeneic hematopoietic stem cell transplantation (HCT). Accurate evaluation of the risk …

PURPOSE: Older adults have unique risk factors for poor outcomes after hematopoietic stem-
cell transplant (HSCT). We sought to determine the impact of our multidisciplinary supportive …

ABSTRACT Young adults (YA), age 18 to 39 years, are at a stage of life that may make them
more vulnerable than older adults to impairments in health-related quality of life (HRQOL) …

Hematopoietic cell transplantation (HCT) remains the only known curative therapy for many
patients with hematologic, metabolic, and immunologic disorders. Furthermore, the use of …

Introduction: Allogeneic hematopoietic cell transplantation (HCT) provides potential cure to a
large number of malignant and nonmalignant hematological disorders. With the …